Patent intelligence · US
US 11162075
Methods and compositions for inducing hematopoietic cell differentiation
Methods and compositions for inducing hematopoietic cell differentiation
Patent details — US 11162075
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 2, 2021
- Expiration
- Oct 28, 2041
- Applicant
- Fate Therapeutics, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K35/28
Quick answer
US 11162075 (Methods and compositions for inducing hematopoietic cell differentiation) is held by Fate Therapeutics, Inc.. Status: granted. Granted Nov 2, 2021. Expires Oct 28, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Fate Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K35/28, A61K35/545, A61K40/10
More from Fate Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419870
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 12410403
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12398373
Enhanced immune effector cells and use thereof
granted -
US 12385012
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12281329
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 12275955
Combining iPSC derived effector cell types for immunotherapy use
granted -
US 12264322
Minimal volume reprogramming of mononuclear cells
granted -
US 12247226
Cellular reprogramming using temporal and transient plasmid vector expression system
granted
Frequently asked questions
What is US patent 11162075?
US 11162075 (Methods and compositions for inducing hematopoietic cell differentiation) is held by Fate Therapeutics, Inc.. Status: granted. Granted Nov 2, 2021. Expires Oct 28, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11162075?
Fate Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.
When does US 11162075 expire?
Our index shows an expiration date of Oct 28, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.